 DUBLIN and SOUTH SAN FRANCISCO, Calif., June 21, 2021 PRNewswire -- Theravance Biopharma, Inc. Theravance Biopharma or the Company NASDAQ: TBPH, a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective medicines, today announced top-line results from its Phase 2 study of 3 mg once-daily nezulcitinib compared to placebo, each in combination with standard of care. 